Anti-nrp1a antibodies and their uses for treating eye or ocular diseases
AssigneeBoehringer Ingelheim International GmbH
InventorsNina ZIPPEL, Pankaj GUPTA, Fei HAN, Yining HUANG, Sarah LOW, Juergen PRESTLE, Leo THOMAS
Life of this patent
Estimating the term…
Abstract
Disclosed are antibodies and fragments thereof that target the A-domain of Neuropilin-1 (Nrp1A). Also disclosed are methods of using the anti-Nrp1A antibodies for the treatment of various diseases or disorders.
Claims19
1-9. (canceled)
A method of for treating or preventing an eye or a retinal disease, the method comprising administering a pharmaceutically effective amount of an anti-Nrp1A antibody or an antigen-binding fragment thereof to a patient in need thereof, wherein said anti-Nrp1A antibody comprises:
- a heavy chain variable region comprising the amino acid sequence of SEQ ID NO:
- 1 (H-CDR1);
- the amino acid sequence of SEQ ID NO:
- 2 (H-CDR2);
- and the amino acid sequence of SEQ ID NO:
- 3 (H-CDR3);
- and
- a light chain variable region comprising the amino acid sequence of SEQ ID NO:
- 4 (L-CDR1);
- the amino acid sequence of SEQ ID NO:
- 5 (L-CDR2);
- and the amino acid sequence of SEQ ID NO:
- 6 (L-CDR3).
(canceled)
20-22. (canceled)
A method of for treating or preventing an eye or a retinal disease, the method comprising administering a pharmaceutically effective amount of an anti-Nrp1A antibody or an antigen-binding fragment thereof that binds to at least one amino acid residue within amino acid regions 68-77 of human Nrp1A as set forth in SEQ ID NO:
- 26 to a patient in need thereof.
A method of for treating or preventing an eye or a retinal disease, the method comprising administering a pharmaceutically effective amount of an anti-Nrp1A antibody or an antigen-binding fragment thereof that binds to the sequence set forth in SEQ ID NO:
- 27 to a patient in need thereof.
A method of for treating or preventing diabetic retinopathy, the method comprising administering a pharmaceutically effective amount of an anti-Nrp1A antibody or an antigen-binding fragment thereof to a patient in need thereof, wherein said anti-Nrp 1A antibody comprises:
- a heavy chain variable region comprising the amino acid sequence of SEQ ID NO:
- 1 (H-CDR1);
- the amino acid sequence of SEQ ID NO:
- 2 (H-CDR2);
- and the amino acid sequence of SEQ ID NO:
- 3 (H-CDR3);
- and
- a light chain variable region comprising the amino acid sequence of SEQ ID NO:
- 4 (L-CDR1);
- the amino acid sequence of SEQ ID NO:
- 5 (L-CDR2);
- and the amino acid sequence of SEQ ID NO:
- 6 (L-CDR3).
A method of for treating or preventing diabetic retinopathy, the method comprising administering a pharmaceutically effective amount of an anti-Nrp1A antibody or an antigen-binding fragment thereof to a patient in need thereof, wherein said anti-Nrp1A antibody comprises:
- a. a heavy chain having an amino acid sequence comprising or consisting of SEQ ID NO:
- 18 and a light chain having an amino acid sequence comprising or consisting of SEQ ID NO:
- 19;
- b. a heavy chain having an amino acid sequence comprising or consisting of SEQ ID NO:
- 20 and a light chain having an amino acid sequence comprising or consisting of SEQ ID NO:
- 19;
- c. a heavy chain having an amino acid sequence comprising or consisting of SEQ ID NO:
- 21 and a light chain having an amino acid sequence comprising or consisting of SEQ ID NO:
- 19;
- d. a heavy chain having an amino acid sequence comprising or consisting of SEQ ID NO:
- 22 and a light chain having an amino acid sequence comprising or consisting of SEQ ID NO:
- 19;
- e. a heavy chain having an amino acid sequence comprising or consisting of SEQ ID NO:
- 23 and a light chain having an amino acid sequence comprising or consisting of SEQ ID NO:
- 19;
- f. a heavy chain having an amino acid sequence comprising or consisting of SEQ ID NO:
- 24 and a light chain having an amino acid sequence comprising or consisting of SEQ ID NO:
- 19;
- or
- g. a heavy chain having an amino acid sequence comprising or consisting of SEQ ID NO:
- 25 and a light chain having an amino acid sequence comprising or consisting of SEQ ID NO:
- 19.
Dependencies are inferred from the claim text.